GSK3B and cancer: In cancers, the hyper‐activation of FGFR4 signalling is a common alteration leading to the activation of various intracellular pathways, including GSK3β/β‐catenin/E‐cadherin [23], FGFR4–GSK3b–Nrf2 signalling [24] and PI3K‐AKT [25].